Craig H Moskowitz, M.D., z is a Professor of Medicine at the Miller School of Medicine, University of Miami Health System, and the Director of Academic Clinician Development, where he oversees the professional growth and success of new and existing clinical faculty within the Sylvester Comprehensive Cancer Center (SCCC). In this role, Dr. Moskowitz designs, implements, and manages mentorship and faculty development programs, focusing on advancing the research capabilities and career trajectories of clinicians. He also helps lead clinical and translational research at SCCC and chairs the Protocol Review and Monitoring Committee.
For seven years, Dr. Moskowitz served as the Physician-in-Chief of the Oncology Service Line at SCCC and Chief Clinical Officer of the cancer center, overseeing outpatient and inpatient clinical care. Prior to joining SCCC, he spent 25 years at Memorial Sloan Kettering Cancer Center in New York, where he directed the Division of Hematologic Oncology and held an endowed chair in lymphoma research.
Dr. Moskowitz’s research focuses on improving outcomes for patients with poor-risk Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). This work has followed two main tracks: (1) optimizing therapy for patients with relapsed and refractory disease, including high-dose therapy (HDT) and autologous stem cell transplant (ASCT), as well as investigating new agents for incorporation into salvage regimens; and (2) developing risk-adapted strategies to optimize treatment for newly diagnosed DLBCL and HL, leveraging insights gained from the relapsed and refractory setting.
His research has contributed to changes in standard of care, including PET-adapted therapies, maintenance therapy post-ASCT, application of clinical and molecular-derived prognostic models in relapsed/refractory disease, and the integration of novel immune-based approaches in the second-line setting. Notably, three agents received approval during these investigations: Brentuximab Vedotin for maintenance therapy post-ASCT in Hodgkin lymphoma, Pembrolizumab for palliation of poor-risk Hodgkin lymphoma, and Loncastuximab Tesirine for patients with relapsed follicular lymphoma.
Throughout his career, Dr. Moskowitz has mentored 24 clinical researchers specializing in lymphoma and leukemia, who are now practicing at institutions across the United States, and is currently mentoring five faculty members at SCCC.
